Media ReleasesStar Combo Pharma

View All Star Combo Pharma News


StarCombo Pharma - Investment Presentation and 1H19 Financial Highlights

Investment Highlights

1H19 revenue growth of 22.9% vs previous corresponding period. EBITDA profitability expected for FY19

- Vertically integrated – Can maximise margins and control supply

- Favourable industry dynamics – Chinese Vitamin and Dietary Supplement demand forecast >US$22 billion by 2020

- Experienced management team – deep understanding of China market and distribution network

- Wholly owned online distribution platform – 5,000 product lines, real-time demand trend analysis

- State of the art manufacturing facility – TGA licensed with excess capacity for anticipated growth

- Pipeline of accretive acquisitions – looking to acquire more profitable brands that can leverage existing manufacturing facility and overseas distribution networks

- Growing pipeline of own products, 9 with China Inspection and Quarantine certification (CIQ) and expecting CIQ for 5 new products

- Experience and knowledge of CIQ registration process

- Ability to innovate – In-house R&D team has the ability to analyse demand, create and bring products to market quickly

- No debt – 1H19 closing net cash of A$7.8m


To view Presentation please download PDF attached: 
Download this document